Genmab Reports Phase 3 EPCORE DLBCL-4 Results Showing Epcoritamab Combination Reduced Disease Progression Risk By Up To 60% In Relapsed Or Refractory DLBCL; Trial Met Its Primary Objective, Demonstrating Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival

뉴스 본문을 불러오고 있어요.

Genmab Reports Phase 3 EPCORE DLBCL-4 Results Showing Epcoritamab Combination Reduced Disease Progression Risk By Up To 60% In Relapsed Or Refractory DLBCL; Trial Met Its Primary Objective, Demonstrating Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival | 웨이프 WAPE

Genmab Reports Phase 3 EPCORE DLBCL-4 Results Showing Epcoritamab Combination Reduced Disease Progression Risk By Up To 60% In Relapsed Or Refractory DLBCL; Trial Met Its Primary Objective, Demonstrating Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival

기사 요약

관련 종목

댓글 —